Sermorelin (GHRH 1-29) Half-Life & Pharmacokinetics — Research Guide (2026)

Research-use only. This guide summarises published pharmacokinetic (PK) data on Sermorelin (GHRH 1-29) for laboratory research and educational reference. Nothing on this page is medical advice or a recommendation for human use.

Sermorelin (GHRH 1-29) is classified as a Truncated 29-residue GHRH analogue (GRF 1-29). Its pharmacokinetic profile — serum half-life, time to peak (Tmax), route-of-administration behaviour, clearance pathway and bioavailability — directly shapes how researchers schedule dosing, interpret PD endpoints and design steady-state experiments.

At-a-Glance Pharmacokinetics

| Parameter | Sermorelin | | --- | --- | | Classification | Truncated 29-residue GHRH analogue (GRF 1-29) | | Serum half-life | Very short serum half-life of approximately 10–20 minutes in published human PK data; the GH pulse it stimulates outlasts the parent peptide. | | Tmax | Tmax of ~5–10 minutes after subcutaneous administration; peak GH response at ~20–30 minutes. | | Validated routes | Subcutaneous administration is the predominant route in published clinical and research studies. | | Bioavailability | Subcutaneous bioavailability is moderate (~60%) in published PK studies; very low oral bioavailability. | | Clearance | Rapid enzymatic clearance via DPP-IV and other endopeptidases; no active metabolites of pharmacological consequence. |

Serum Half-Life

Very short serum half-life of approximately 10–20 minutes in published human PK data; the GH pulse it stimulates outlasts the parent peptide.

The functional implication is that steady-state PK is reached at approximately 4–5 half-lives. For Sermorelin, that informs how quickly researchers can expect plasma exposure to stabilise across repeat dosing.

Time to Peak (Tmax)

Tmax of ~5–10 minutes after subcutaneous administration; peak GH response at ~20–30 minutes.

Tmax is the parameter that most directly governs acute pharmacodynamic readouts. For GH-axis peptides this dictates blood-sampling timing for stimulated GH; for incretin analogues it shapes the post-prandial glucose challenge window.

Routes of Administration

Subcutaneous administration is the predominant route in published clinical and research studies.

Bioavailability across routes: Subcutaneous bioavailability is moderate (~60%) in published PK studies; very low oral bioavailability.

Clearance & Metabolism

Rapid enzymatic clearance via DPP-IV and other endopeptidases; no active metabolites of pharmacological consequence.

Key Pharmacokinetic Takeaways

• Among the shortest-acting GH-axis peptides — supports physiologic pulsatile GH release
• Bedtime dosing aligns the stimulated GH pulse with endogenous nocturnal release in research protocols
• Rapid clearance limits negative feedback compared with longer-acting analogues like CJC-1295 DAC
• Tachyphylaxis is minimal at standard research doses due to preserved pulsatility

Frequently Asked Questions

What is the half-life of Sermorelin? Very short serum half-life of approximately 10–20 minutes in published human PK data; the GH pulse it stimulates outlasts the parent peptide.

How quickly does Sermorelin reach peak concentration? Tmax of ~5–10 minutes after subcutaneous administration; peak GH response at ~20–30 minutes.

Which routes of administration are validated in published research? Subcutaneous administration is the predominant route in published clinical and research studies.

Does Sermorelin accumulate with repeat dosing? Rapid enzymatic clearance via DPP-IV and other endopeptidases; no active metabolites of pharmacological consequence. Steady-state is typically reached at 4–5 half-lives in published multi-dose studies.

Is oral bioavailability meaningful for Sermorelin? Subcutaneous bioavailability is moderate (~60%) in published PK studies; very low oral bioavailability.

Related Research

• Reconstitution & storage protocols — see the Sermorelin reconstitution guide for vial handling that preserves the PK profile described above.
• Dosing protocols research — see the Sermorelin dosing protocols article for how PK parameters translate into scheduling decisions.
• Mechanism of action — see the Sermorelin mechanism guide for the receptor-level basis of the PD effects driven by the PK profile.

---

*Sources cited inline are drawn from published preclinical and clinical pharmacokinetic literature. This article is for laboratory research and educational use only and does not constitute medical advice.*